Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Klaus P Hoeflich

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Nature|August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersGeorgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
Cancer Discovery|May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistanceSi Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Journal of Medicinal Chemistry|January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitorsSteven T Staben, Jianwen A Feng, Karen Lyle, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L Sos, Stefanie Fischer, Roland Ullrich, et al.
Breast Cancer Research : BCR|April 24, 2015
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agentsChristy C Ong, Sarah Gierke, Cameron Pitt, et al.
Genome Research|October 4, 2012
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing eventsJinfeng Liu, William Lee, Zhaoshi Jiang, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Nature|August 13, 2013
Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancersGeorgia Hatzivassiliou, Jacob R Haling, Huifen Chen, et al.
Nature|February 5, 2010
RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growthGeorgia Hatzivassiliou, Kyung Song, Ivana Yen, et al.
Cancer Discovery|May 16, 2012
PPM1H is a p27 phosphatase implicated in trastuzumab resistanceSi Tuen Lee-Hoeflich, Thinh Q Pham, Don Dowbenko, et al.
Journal of Medicinal Chemistry|January 18, 2014
Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitorsSteven T Staben, Jianwen A Feng, Karen Lyle, et al.
ACS Medicinal Chemistry Letters|December 30, 2015
Design of Selective PAK1 Inhibitor G-5555: Improving Properties by Employing an Unorthodox Low-pK a Polar MoietyChudi O Ndubaku, James J Crawford, Joy Drobnick, et al.
The Journal of Pathology|July 31, 2014
PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibitionWei Zhou, Adrian M Jubb, Karen Lyle, et al.
Journal of Medicinal Chemistry|May 12, 2016
Chemically Diverse Group I p21-Activated Kinase (PAK) Inhibitors Impart Acute Cardiovascular Toxicity with a Narrow Therapeutic WindowJoachim Rudolph, Lesley J Murray, Chudi O Ndubaku, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 7, 2009
Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancerMartin L Sos, Stefanie Fischer, Roland Ullrich, et al.
Breast Cancer Research : BCR|April 24, 2015
Small molecule inhibition of group I p21-activated kinases in breast cancer induces apoptosis and potentiates the activity of microtubule stabilizing agentsChristy C Ong, Sarah Gierke, Cameron Pitt, et al.
Genome Research|October 4, 2012
Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing eventsJinfeng Liu, William Lee, Zhaoshi Jiang, et al.
Pageof 7